Is there still a role for talimogene laherparepvec (T-VEC) in advanced melanoma? An indirect efficacy comparison of T-VEC plus ipilimumab combination therapy versus T-VEC alone as salvage therapy in unresectable metastatic melanoma

References

• Andtbacka RHI, Collichio F, and Harrington KJ, et al. Final analyses of OPTiM: a randomized phase III trial of talimogene laherparepvec versus granulocyte-macrophage colony-stimulating factor in unresectable stage III-IV melanoma. J Immunother Cancer. 2019;7(1):145.
   PubMed Web of Science ®Google Scholar
• Sun L, Funchain P, and Song JM, et al. Talimogene Laherparepvec combined with anti-PD-1 based immunotherapy for unresectable stage III-IV melanoma: a case series. J Immunother Cancer. 2018;6(1):36.
   PubMedGoogle Scholar
• Raman S, Hecht J, Chan E. Talimogene laherparepvec: review of its mechanism of action and clinical efficacy safety. Immunotherapy. 2019;11(8):705–723.
   PubMed Web of Science ®Google Scholar
• Frohlich A, Niebel D, Fietz S, et al. Talimogene laherparepvec treatment to overcome loco-regional acquired resistance to immune checkpoint blockade in tumor stage IIIB-IV M1c melanoma patients. Cancer Immunol Immunother. 2020;65(5):759–769.
   Google Scholar
• Andtbacka RHI, Kaufman HL, Collichio F, et al. Talimogene laherparepvec improves durable response rate in patients with advanced melanoma. J Clin Oncol. 2015;33(25):2780–2788.
   PubMed Web of Science ®Google Scholar
• Franke V, Berger DMS, Klop WMC, et al. High response rates for T-VEC in early metastatic melanoma (stage IIIB/C-IVM1a). IJC. 2019;145:974–978.
   Google Scholar
• Coit DG, Thompson JA, Albertini MR, et al. Cutaneous melanoma, version 2.2019. JCCN. 2019;17(4):368–402.
   Google Scholar
• Moesta AK, Cooke K, Piasecki J. Local delivery of OncoVEX(mGM-CSF) generates systemic anti-tumor immune responses enhanced by cytotoxic T- lymphocyte-associated protein blockade. Clin Cancer Res. 2017;23:6190–6202.
   PubMed Web of Science ®Google Scholar
• Weber J, Mandala M, Del Vecchio M, et al. Adjuvant Nivolumab versus ipilimumab in resected stage III or IV melanoma. N Engl J Med. 2017;377:1824–1835.
   PubMed Web of Science ®Google Scholar
• Robert C, Schachter J, Long GV. Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med. 2015;372(26):2521–2532.
   PubMed Web of Science ®Google Scholar
• Larkin J, Chiarion-Sileni V, Gonzalez R, et al. Five-year survival with combined nivolumab and ipilimumab in advanced melanoma. N Engl J Med. 2019;381:1535–1546.
   PubMed Web of Science ®Google Scholar
• Afzal MZ, Shirai K. Response to the rechallenge with talimogene laherparepvec (T-VEC) after ipilimumab/nivolumab treatment in patient with cutaneous malignant melanoma who initially had a progression on T-VEC with pembrolizumab. J Immunother. 2019;42(4):136–141.
   PubMed Web of Science ®Google Scholar
• Puzanov I, Milhem MM, Minor D, et al. Talimogene laherparepvec in combination with ipilimumab in previously untreated, unresectable stage IIIB-IV melanoma. J Clin Oncol. 2016;34(22):2619–2626.
   PubMed Web of Science ®Google Scholar
• Chesney J, Puzanov I, and Collichio F, et al. Randomized, open-label phase II study evaluating the efficacy and safety of talimogene laherparepvec in combination with ipilimumab versus ipilimumab alone in patients with advanced, unresectable melanoma. J Clin Oncol. 2018;36(17):1658–1667.
   PubMed Web of Science ®Google Scholar
• Caro JJ, Ishak KJ. No head-to-head trial? Simulate the missing arms. PharmacoEconomics. 2010;28(10):957–967.
   PubMed Web of Science ®Google Scholar
• Signorovitch JE, Sikirica V, Erder MH, et al. Matching-adjusted indirect comparisons: a new tool for timely comparative effectiveness research. Value Health. 2012;15(6):940–947.
   PubMed Web of Science ®Google Scholar
• Quinn C, Ma Q, Kudlac A, et al. Indirect treatment comparison of talimogene laherparepvec compared with ipilimumab and vemurafenib for the treatment of patients with metastatic melanoma. Adv Ther. 2016;33(4):643–657.
   PubMed Web of Science ®Google Scholar
• Korn EL, Liu P-Y, Lee SJ, et al. Meta-analysis of phase II cooperative group trials in metastatic stage IV melanoma to determine progression-free and overall survival benchmarks for future phase II trials. J clin oncol. 2008;26(4):527–534.
   PubMed Web of Science ®Google Scholar
• Mitchell M, Muftakhidinov B, Tobias Winchen TA. “Engauge digitizer software”. Available from: http://markummitchell.github.io/engauge-digitizer.
   Google Scholar
• Guyot P, Ades AE, Ouwens MJNM, et al. Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves. BMC Med Res Methodol. 2012;12(1):9.
   PubMed Web of Science ®Google Scholar
• Long G, Dummer R, Johnson D, et al. Long-term analysis of MASTERKEY-265 phase IB trial of talimogene laherparepvec (T-VEC) plus pembrolizumab in patients with unresectable stage IIIB-IVM1c melanoma. J Immunother Cancer. 2020;8:A261.
   Web of Science ®Google Scholar
• Ribas A, Drummer R, Puzanov I, et al. Oncolytic virotherapy promotes intratumoral T cell infiltration and improves anti-PD-1 immunotherapy. Cell. 2017;170:1109–1119.
   PubMed Web of Science ®Google Scholar
• National Library of Medicine (US). 2017. A Phase II study of combining talimogene laherparepvec (T-VEC) (NSC-785349) and MK-3475 (pembrolizumab) (NSC-776864) in patients with advanced melanoma who have progressed on anti-PD1/L1 based therapy. Identifier: NCT02965716. Identifier: NCT02965716. [cited 2021 Sep 21]. Available from: https://clinicaltrials.gov/ct2/show/NCT02965716
   Google Scholar
• Puzanov I, Ribas A, Robert C, et al. Association of BRAF V600E/K mutation status and prior BRAF/MEK inhibition with pembrolizumab outcomes in advanced melanoma. JAMA Oncol. 2020;6(8):1256–1264.
   PubMed Web of Science ®Google Scholar
• Hodi FS, O’Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363:711–723.
   PubMed Web of Science ®Google Scholar
• Weber JS, Gibney G, Sullivan RJ, et al. Sequential administration of nivolumab and ipilimumab with a planned switch in patients with advanced melanoma (CheckMate 064): an open-label, randomised, phase 2 trial. Lancet Oncol. 2016;17(7):943–955.
   PubMed Web of Science ®Google Scholar
• Zimmer L, Apuri S, Eroglu Z, et al. Ipilimumab alone or in combination with nivolumab after progression on anti-PD-1 therapy in advanced melanoma. Eur J Cancer. 2017;75:47–55.
   PubMed Web of Science ®Google Scholar
• Harrington KJ, Michielin O, and Malvehy J, et al. A practical guide to handling and administration of talimogene laherparepvec in Europe. Onco Targets Ther. 2017;10:3867–3880.
   PubMed Web of Science ®Google Scholar